Eosinophilic Esophagitis
Dupixent bests placebo in clinical, histological outcomes in patients with EoE
CHARLOTTE, N.C. — Dupilumab improved clinical, symptomatic, histologic and endoscopic outcomes among patients treated for eosinophilic esophagitis, according to study results presented at the ACG Annual Scientific Meeting.
VIDEO: Model accurately rules out likelihood of EoE, prevents ‘unnecessary biopsies’
CHARLOTTE, N.C. — In a Healio video exclusive, Amrit Kamboj, MD, a gastroenterologist at Mayo Clinic Rochester, reported a predictive model accurately identified patients’ likelihood of eosinophilic esophagitis.
Top news of September: Penicillin allergy de-labeling, hidden food allergies, more
Healio compiled the most-read news in allergy, asthma and immunology posted in September.
Distensibility index superior measure for fibrostenotic severity in children with EoE
The distensibility index provides a superior metric for fibrostenotic severity vs. esophageal diameter alone in pediatric patients with eosinophilic esophagitis, according to research published in Clinical Gastroenterology and Hepatology.
Vitamin D supplementation mitigates inflammation in eosinophilic esophagitis
Supplementation with vitamin D may alleviate allergic inflammation in the esophagus, whereas a deficiency in vitamin D may lead to a higher risk for eosinophilic esophagitis and other allergic states, according to a study published in Gut.
Household detergent exposure may be linked to eosinophilic esophagitis
Sodium dodecyl sulfate, a common household detergent, decreased the integrity of the esophageal barrier, stimulated IL-33 production and promoted epithelial hyperplasia and tissue eosinophilia, according to a study published in Allergy.
Patients with eosinophilic esophagitis symptoms may benefit from gastric emptying studies
Gastric emptying studies may benefit patients with persistent symptoms of eosinophilic esophagitis who do not respond to treatment, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Dupilumab confers remission of eosinophilic esophagitis among young children
Children aged 1 to 11 years with eosinophilic esophagitis safely achieved histologic disease remission after 16 weeks of treatment with the fully human monoclonal antibody dupilumab, according to the results of a phase 3 trial.
Q&A: FDA approval of dupilumab for eosinophilic esophagitis a ‘victory for rare diseases’
The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in adults and children aged 12 years and older, making it the first drug in the U.S. specifically indicated for this condition.
Top in GI: Gallstone disease and pancreatic cancer; new eosinophilic esophagitis drug
A presenter at Digestive Disease Week reported that gallstone disease may be a predictor of pancreatic cancer.